An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression of Alzheimer’s disease in closely watched trials.
Semaglutide fails to slow progression of Alzheimer’s in highly anticipated trials, Novo Nordisk says
Related Posts
-
QB Brendan Sorsby enters treatment program for a gambling addiction
He was one of the biggest names in this year’s transfer portal, and left Cincinnati…
-
AI boosts costs as pricing power lags, say Indian telcos
AI is raising network costs without a corresponding increase in revenues, according to India’s operators.
-
Iowa Senate passes ‘Make America Healthy Again’ bill restricting SNAP purchases
The Iowa Senate has passed the controversial “Make America Healthy Again” Act, restricting SNAP purchases…
-
Docuseries investigates claims of serial killings in western Iowa
A woman has made allegations that her late father killed up to 70 women and…
Leave a Reply